详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Shi Yuankai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] * ; Li Jin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Xu Jianming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Cheng Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Liu Wei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Cheng Yigui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Bai Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhang Yiping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; He Xiaohui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Luo Yi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Liu Yunpeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Yao Qiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Li Yuhong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Qin Shukui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; HU Xiaohua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Guo Yajun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Sun Yan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ;

机构： [1]National Cancer Center /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Chinical Study on Anticancer Molecular Targeted Drugs, Beijing, China [2]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [3]Beijing 307 Hospital, Beijing, China [4]Jilin Cancer Hospital, Changchun, China [5]The 4th Hospital of Hebei Medical University, Shijiazhuang, China [6]Fujian Cancer Hospital, Fuzhou, China [7]Beijing 301 PLA Hospital, Beijing, China [8]Zhejiang Cancer Hospital, Hangzhou, China [9]Hunan Provincial Tumor Hospital, Changsha, China [10]The First Hospital of China Medical University, Shenyang, China [11]Tianjin People's Hospital, Tianjin, China [12]Sun Yat-Sen University Cancer Center, Guangzhou, China [13]PLA 81 Hospital, Nanjing, China [14]The Affiliated Cancer Hospital of Guangxi Medical University, Guangxi, China [15]State Key Laboratory of Antibody Medicine And Targeted Therapy, Shanghai, China

出处：

DOI：

ISSN：

语种：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

第一作者：

第一作者机构： [1]National Cancer Center /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Chinical Study on Anticancer Molecular Targeted Drugs, Beijing, China [2]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [3]Beijing 307 Hospital, Beijing, China [4]Jilin Cancer Hospital, Changchun, China [5]The 4th Hospital of Hebei Medical University, Shijiazhuang, China [6]Fujian Cancer Hospital, Fuzhou, China [7]Beijing 301 PLA Hospital, Beijing, China [8]Zhejiang Cancer Hospital, Hangzhou, China [9]Hunan Provincial Tumor Hospital, Changsha, China [10]The First Hospital of China Medical University, Shenyang, China [11]Tianjin People's Hospital, Tianjin, China [12]Sun Yat-Sen University Cancer Center, Guangzhou, China [13]PLA 81 Hospital, Nanjing, China [14]The Affiliated Cancer Hospital of Guangxi Medical University, Guangxi, China [15]State Key Laboratory of Antibody Medicine And Targeted Therapy, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.

文献详情